UNSPSC 51172710: Hyoscyamine/methenamine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GU209. This VA Drug Class (GU209) classifies this compound as belonging to the group ANTISPASMODICS, URINARY, OTHER.

UNSPSC 51172710 Hyoscyamine/methenamine is a Commodity code covering a specific pharmaceutical active ingredient, but recent state and local procurement activity under this code shows limited direct solicitation for the ingredient itself; instead, opportunities reflect broader drug testing, pharmacy benefit management, and pharmaceutical supply contracting where such products may be components of larger service or supply frameworks. The actual buying pattern includes specimen collection and drug screening services (where confirmatory testing may involve related compounds), generic pharmaceutical supply agreements through cooperative purchasing, and pharmacy benefit program initiatives that encompass multiple therapeutic categories and OTC products rather than hyoscyamine/methenamine as a standalone line item.

Issuing bodies soliciting under this code span state health and human services departments, county criminal justice supervision agencies, and multistate cooperative purchasing alliances. Collin County Community Supervision and Corrections Department (Texas) issued an RFP on July 9, 2026 for offender specimen collection and drug testing services due July 23, 2026, with an estimated contract value of $600,000 over two years plus optional renewals; the scope includes immunoassay screening with confirmation testing and alternative methodologies (oral fluid, hair) across two collection sites in the Dallas-Fort Worth region, with approximately 25,031 tests annually. The Texas Health and Human Services Commission issued an RFI on April 3, 2026 seeking vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued an RFP on January 20, 2026 (response deadline March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers across participating state and local facilities including Oregon, with contract effectiveness July 1, 2026. Geographic activity clusters in Texas and the upper Midwest, with cooperative purchasing extending across multiple states. The code shows limited standalone activity for hyoscyamine/methenamine; procurement professionals should evaluate whether opportunities are captured under higher-tier pharmaceutical supply or drug testing service codes rather than this specific ingredient-level Commodity designation.